Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis

Clinical Nephrology

Volumn 62, Issue 3, 2004, Pages 193-201

  Finn, W F ^a   Joy, M S ^a   Hladik, G ^a   Garrett, L ^b   Godwin, J ^b   Schmidt, R ^b   Wombolt, D ^b   Richards, V ^b   Smith, W ^b   Galphin, C ^b   Moore, M ^b   Moore, R ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Chronic renal failure; Hemodialysis; Hyperparathyroidism; Hyperphosphatemia; Lanthanum carbonate; Phosphate binding agent

Indexed keywords

CALCIUM; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DYSPEPSIA; FEMALE; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; OUTCOMES RESEARCH; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VOMITING;

EID: 4544334174     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp62193     Document Type: Article

References (35)

1. Ackrill P, Day JP, Ahmed R 1998 Aluminum and iron overload in chronic dialysis. Kidney Int 24 (Suppl 1): S163-S167
2. Alfrey AC, Ibels LS 1978 Role of phosphate and pyrophosphate in soft tissue calcification. Adv Exp Med Biol 103: 187-193
3. Angelis M, Wong LL, Myers SA, Wong LM 1997 Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 122: 1083-1090
4. Bleyer AJ, Burke SK, Dillon M et al 1999 A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33: 694-701
5. Block GA, Hulbert-Shearon TE, Levin NW, Port FK 1998 Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31: 607-617
6. Block GA, Port FK 2000 Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 35: 1226-1237
7. Braun J, Oldendorf M, Moshage W et al 1996 Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27: 394-401
8. Chertow GM, Burke SK, Lazarus JM et al 1997 Poly[allylamine Hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29: 66-71
9. Damment SJP, Webster I 2003 The pharmacology of lanthanum carbonate (Fosrenol): a novel nonaluminum noncalcium phosphate binder. Poster presented at the 36th Annual Meeting of the American Society of Nephrology, San Diego, CA, USA
10. Delmez JA, Slatopolsky E 1992 Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 19: 303-317
11. Dewberry K, Fox JS, Stewart J, Murray JR, Hutchison AJ 1997 Lanthanum carbonate: a novel noncalcium containing phosphate binder. J Am Soc Nephrol 8: 560A
12. D'Haese PC, Spasovski GB, Sikole A et al 2003 Multicentre study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 63 (Suppl 85): S73-S78
13. Drüeke TB 2002 Intestinal absorption of aluminum in renal failure. Nephrol Dial Transplant 17 (Suppl 2): 13-16
14. Goodman WG, Goldin J, Kuizon ED et al 2000 Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483
15. Graff L, Burnel D 1995 A possible nonaluminum oral phosphate binder? A comparative study on dietary phosphorus absorption. Res Commun Mol Pathol Pharmacol 89: 373-388
16. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG 1993 Aplastic osteodystrophy without aluminum: the role of " suppressed" parathyroid function. Kidney Int 44: 860-866
17. Hruska KA 1997 Renal osteodystrophy. Baillieres Clin Endocrinol Metab 11: 165-194
18. Hsu CH 1997 Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 29: 641-649
19. Jing J, Kawashima A, Sickler K, Raval EK, Oldham SA 1998 Metastatic cardiac calcification in a patient with chronic renal failure who was undergoing hemodialysis: radiographic and CT findings. Am J Roentgenol 170: 903-905
20. Joy M, Finn WF, on behalf of the LAM 302 Study Group 2003 Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 46: 92-107
21. Kates DM, Andress DL 1996 Control of hyperphosphatemia in renal failure: role of aluminum. Semin Dial 9: 310-315
22. Kuroda S, Komori M, Nagamatsu K et al 1995 Effect of iron as a new type of phosphate binder in hemodialysis patients. Nippon Jinzo Gakkai Shi 37: 468-473
23. Lau AH, Kuk JM, Franson KL 1998 Phosphate-binding capacities of calcium and aluminum formulations. Int J Artif Organs 21: 19-22
24. Locatelli F, D'Amico M, Pontoriero G 2003 Lanthanum carbonate. Curr Opin Invest Drugs 4: in press
25. Lundin AP, Adler AJ, Feinroth MV, Berlyne GM, Friedman EA 1980 Maintenance hemodialysis: survival beyond the first decade. J Am Med Assoc 244: 38-40
26. Malluche HH, Faugere MC 1992 Risk of adynamic bone disease in dialyzed patients. Kidney Int 42: 62-67
27. 3? Perit Dial Int 9: 325-328
28. Pei I, Hercz G, Greenwood C et al 1995 Risk factors for renal osteodystrophy: a multivariant analysis. J Bone Miner Res 10: 149-156
29. Pennick M, Damment SJP, Gill M 2003 The pharmacokinetics and tissue distribution of lanthanum carbonate (Fosrenol), a new nonaluminum, noncalcium phosphate binder. Poster presented at the 36th Annual Meeting of the American Society of Nephrology (ASN), San Diego, CA, USA
30. Rubel JR, Milford EL 2003 The relationship between serum calcium and phosphate levels and cardiac valvular procedures in the hemodialysis population. Am J Kidney Dis 41: 411-421
31. Savory J, Bertholf RL, Wills MR 1985 Aluminum toxicity in chronic renal insufficiency. Clin Endocrinol Metab 14: 681-702
32. Spengler K, Follmann H, Boos K et al 1996 Cross-linked iron dextran is an efficient oral phosphate binder in the rat. Nephrol Dial Transplant 11: 808-812
33. Tzamaloukas AH 1990 Diagnosis and management of bone disorders in chronic renal failure and dialyzed patients. Med Clin North Am 74: 961-974
34. Validation Report for Lanthanum in Blood Plasma by ICP-MS 2000 Report March 10. Research Triangle Institute, Research Triangle Park, NC, USA
35. Zacharias JM, Fontaine B, Fine A 1999 Calcium use increases risk of calciphylaxis: a case-control study. Perit Dial Int 19: 248-252